NU7441 (KU-57788): Selective ATP-Competitive DNA-PK Inhibitor for Oncology and DNA Repair Research

Executive Summary: NU7441 (KU-57788) is an ATP-competitive DNA-PK inhibitor with an IC50 of ~13–14 nM and a Ki of 0.65 nM, showing high selectivity over ATM and ATR even at 100 μM concentrations (APExBIO). NU7441 is insoluble in water and ethanol but dissolves in DMSO at ≥4.13 mg/mL. In vitro, it sensitizes cancer cell lines to DNA-damaging agents and causes G1-phase cell cycle arrest (Kostaras et al. 2020). In vivo, 10 mg/kg intraperitoneal administration doubles the tumor growth delay induced by etoposide phosphate in SW620 xenografts. NU7441 thus enables precise interrogation of DNA repair, oncology, and cell cycle regulation workflows.

Biological Rationale

DNA-dependent protein kinase (DNA-PK) is a central mediator in the non-homologous end joining (NHEJ) pathway, responsible for repairing DNA double-strand breaks (DSBs) in eukaryotic cells. Aberrant activation of DNA-PK is implicated in tumor resistance to DNA-damaging therapies (Kostaras et al. 2020). Selective inhibition of DNA-PK disrupts efficient DSB repair, sensitizing cancer cells to ionizing radiation and chemotherapeutic agents. NU7441 (KU-57788) is designed to competitively inhibit the catalytic activity of DNA-PK, offering a robust tool for dissecting the DNA damage response pathway. Compared to broad-spectrum PI3K inhibitors, NU7441 demonstrates high selectivity and minimal off-target effects, which is critical for mechanistic studies and translational oncology research (Related Content).

Mechanism of Action of NU7441 (KU-57788)

NU7441 (KU-57788) acts as a highly potent, ATP-competitive inhibitor of DNA-PK. It binds to the ATP-binding pocket of the DNA-PK catalytic subunit (DNA-PKcs), preventing phosphorylation events critical for NHEJ-mediated DNA repair. The compound exhibits an IC50 of approximately 13–14 nM and a Ki of 0.65 nM for DNA-PK in cell-free enzymatic assays (pH 7.4, 25°C) (APExBIO). At concentrations up to 100 μM, NU7441 demonstrates negligible inhibition of related kinases ATM and ATR, and only weak inhibition of mTOR (IC50 = 1.7 μM) and PI3K (IC50 = 5 μM) (Related Article). This high selectivity profile distinguishes it from pan-PI3K inhibitors, allowing for focused perturbation of the DNA damage response with minimal confounding effects on the PI3K/Akt/mTOR pathway.

Evidence & Benchmarks

• NU7441 inhibits DNA-PK with an IC50 of ~13–14 nM and Ki of 0.65 nM in vitro (APExBIO, product page).
• NU7441 shows <10% inhibition of ATM and ATR at concentrations up to 100 μM (Kostaras et al. 2020).
• IC50 values for mTOR and PI3K are 1.7 μM and 5 μM, respectively, indicating weak off-target activity (APExBIO).
• NU7441 sensitizes HeLa, LoVo, and SW620 cancer cell lines to etoposide and ionizing radiation, enhancing cytotoxicity and cell cycle arrest in G1 phase (Kostaras et al. 2020).
• In SW620 xenograft mouse models, 10 mg/kg i.p. NU7441 plus etoposide phosphate doubles tumor growth delay versus etoposide alone (APExBIO).
• NU7441 is insoluble in ethanol and water, but soluble in DMSO at ≥4.13 mg/mL (APExBIO, product page).
• Recommended storage is -20°C; long-term storage of solutions is discouraged (APExBIO, product page).

Applications, Limits & Misconceptions

NU7441 (KU-57788) is a benchmark compound for research in DNA repair, oncology, and cell cycle regulation. Its high specificity enables clean mechanistic studies of DNA-PK function and downstream pathways including the DNA damage response, cell cycle checkpoints, and caspase signaling. The compound is widely used in cell cycle arrest assays and studies of sensitization to DNA-damaging agents (Contrast: This article details new in vivo benchmarks not covered in the cited review.). Its defined selectivity profile allows researchers to attribute observed phenotypes to DNA-PK inhibition, minimizing confounding effects from PI3K/Akt/mTOR cross-reactivity (Extension: Here, we integrate updated cell line data and workflow parameters.).

Common Pitfalls or Misconceptions

• NU7441 is not a pan-PI3K inhibitor: Its activity against PI3K and mTOR is weak (IC50 ≥ 1.7 μM), limiting its use for broad PI3K pathway inhibition.
• Solubility limitations: NU7441 is insoluble in water and ethanol, requiring DMSO as a solvent for in vitro and in vivo studies.
• Storage stability: Long-term storage of prepared solutions reduces potency; only solid compound should be stored at -20°C for extended periods.
• Non-applicability in ATM/ATR-driven models: Minimal inhibition of ATM/ATR means NU7441 is not suitable for studies targeting these kinases directly.
• Not suitable for routine clinical use: NU7441 is a research tool and not approved for therapeutic application in humans.

Workflow Integration & Parameters

NU7441 (KU-57788) is supplied by APExBIO as a solid compound (SKU: A8315). For most cellular assays, stock solutions are prepared in DMSO at concentrations ≥4.13 mg/mL and diluted into the desired assay buffer shortly before use. Recommended working concentrations range from 10–1000 nM depending on cell line sensitivity and endpoint (Update: This article incorporates strategic in vivo titration guidance.). For in vivo studies, intraperitoneal administration at 10 mg/kg is well-tolerated and effective in SW620 xenograft models when used in combination with DNA-damaging agents such as etoposide phosphate. Standard endpoints include assessment of DNA damage (γ-H2AX foci), cell cycle distribution (flow cytometry), and viability/proliferation (MTT, clonogenic survival). Proper controls must include vehicle (DMSO) and, where relevant, DNA-PK wild-type and knockout models for specificity validation.

Conclusion & Outlook

NU7441 (KU-57788) is a highly selective, ATP-competitive inhibitor of DNA-PK that enables precise dissection of DNA repair mechanisms and the DNA damage response in oncology research. Its nanomolar potency, minimal off-target effects, and validated in vivo efficacy make it an essential tool for cell cycle arrest assays, combinatorial sensitization studies, and investigations of the PI3K/Akt/mTOR axis. While not suitable for clinical applications, NU7441 sets the benchmark for tool compounds in DNA-PK research and is available from APExBIO for research use only. For expanded workflows and troubleshooting guidance, see scenario-based protocols (Contrast: This article provides troubleshooting and assay optimization details not covered in this overview.).